Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

BACKGROUND: Dupilumab has proven to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, real-world experience with dupilumab in a broader population is limited. METHODS: The study population comprised adult patients with moderate-to-seve...

Full description

Bibliographic Details
Main Authors:	Argenziano, G. (Author), Bonzano, L. (Author), Calabrese, G. (Author), Carbonara, M. (Author), Detoraki, C. (Author), Di Bona, D. (Author), Di Leo, E. (Author), Fabbrocini, G. (Author), Ferrucci, S.M (Author), Foti, C. (Author), Macchia, L. (Author), Napolitano, M. (Author), Nettis, E. (Author), Nisticò, S.P (Author), Ortoncelli, M. (Author), Patruno, C. (Author), Pellacani, G. (Author), Piras, V. (Author), Ribero, S. (Author), Romita, P. (Author), Rongioletti, F. (Author), Tavecchio, S. (Author)
Format:	Article
Language:	English
Published:	NLM (Medline) 2022
Subjects:	adult Adult Antibodies, Monoclonal, Humanized atopic dermatitis Atopic dermatitis clinical trial conjunctivitis Conjunctivitis Dermatitis, Atopic dupilumab Dupilumab human Humans immunoglobulin E Immunoglobulin E monoclonal antibody Multicenter real-life study multicenter study Retrospective Studies retrospective study severity of illness index Severity of Illness Index treatment outcome Treatment Outcome
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Internet

Similar Items